RASSF1A, BLU, NORE1A, PTEN and MGMT expression and promoter methylation in gliomas and glioma cell lines and evidence of deregulated expression of de novo DNMTs.
about
A functional polymorphism in the DNA methyltransferase-3A promoter modifies the susceptibility in gastric cancer but not in esophageal carcinomaO6-Methylguanine-DNA methyltransferase protein expression by immunohistochemistry in brain and non-brain systemic tumours: systematic review and meta-analysis of correlation with methylation-specific polymerase chain reaction.O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation.Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various gradesIdentification of valid endogenous control genes for determining gene expression in human glioma.Role of RASSF1A promoter methylation in the pathogenesis of hepatocellular carcinoma: a meta-analysis of 21 cohort studies.MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCROverexpression of DNA methyltransferase 1 (DNMT1) protein in astrocytic tumour and its correlation with O6-methylguanine-DNA methyltransferase (MGMT) expressionComparative genomic and genetic analysis of glioblastoma-derived brain tumor-initiating cells and their parent tumors.BRAF, GNAQ, and GNA11 mutations and copy number in pediatric low-grade gliomaIdentification of cilia genes that affect cell-cycle progression using whole-genome transcriptome analysis in Chlamydomonas reinhardtti.Detection of MGMT, RASSF1A, p15INK4B, and p14ARF promoter methylation in circulating tumor-derived DNA of central nervous system cancer patientsEpigenetic changes in gliomas.High incidence of MGMT and RARbeta promoter methylation in primary glioblastomas: association with histopathological characteristics, inflammatory mediators and clinical outcome.Epigenetic regulation of gene expression in physiological and pathological brain processes.Unraveling the glioma epigenome: from molecular mechanisms to novel biomarkers and therapeutic targets.Genetic and pathologic evolution of early secondary gliosarcoma.Downregulation of nitrogen permease regulator like-2 activates PDK1-AKT1 and contributes to the malignant growth of glioma cells.Ras signaling through RASSF proteins.RASSF5A, a candidate tumor suppressor, is epigenetically inactivated in esophageal squamous cell carcinoma.In Silico Enhanced Restriction Enzyme Based Methylation Analysis of the Human Glioblastoma Genome Using Agilent 244K CpG Island Microarrays.Aberrant CpG islands hypermethylation profiles in malignant gliomas.DNA methylation, histone modifications, and signal transduction pathways: a close relationship in malignant gliomas pathophysiology.Analysis of CIC-associated CpG island methylation in oligoastrocytoma.Tumor suppressor gene BLU is frequently downregulated by promoter hypermethylation in myelodysplastic syndrome.
P2860
Q33529283-EE0F86DD-E47A-4BA2-AED5-84CBB0129C9DQ33804528-15DC3B69-D5FF-43F3-BD8C-9AA01EB8D258Q33834163-E5245867-19F7-4CC8-B1EB-728329D91742Q34132740-DF53D373-A5C7-4240-9E57-7F67EE5B46FEQ34132923-1A97A989-8822-46F9-BFEC-D3AC7E4571E0Q35102439-0DCCAEF6-9D49-4456-852B-40F75FA2B7B3Q35850389-9F15EE2B-F532-45D0-9D65-7566C34B8C25Q35918897-F9A4B6A3-A993-405D-A989-E4153569B86BQ36618220-8CD4D189-34E6-40AC-9156-2636F43787CCQ36811872-7563875C-78F9-4D74-8E88-D847FE3DB1D7Q36947278-2685E07A-EA9D-45CB-B608-374E59647F7AQ37039354-362D9642-5FCB-4ECE-A3B9-6A52A4B3281BQ37287032-81CBE160-4F7E-470D-BAEE-4F1245E2D62EQ37375205-21444903-D2C9-4363-873E-0574E8F46A4EQ37870034-153A1C14-66F1-4954-8FA0-0DAFAB6397CCQ37937061-3BFF2E38-BA0D-4907-B322-16E522E6EE10Q38820020-9F583B32-211B-460F-A0DF-B5EB5C600D3FQ38828889-53AD68C4-298B-4ED6-A79B-3EE7EC9F19DBQ38862017-193711F9-D01B-4D35-8A6D-89CB06DBF326Q38920937-F069F2C9-40E8-4DBD-99E0-E64CD1C2EB97Q40156702-94582ADE-9775-4E35-94EE-A0A4D8B2EB66Q40444258-2A6972C5-B6C0-46C7-BF42-BB1DB6C586A3Q42090451-FA243FD5-8B7C-4845-84F8-EFD3F6222713Q48114529-D02142CF-7E12-40B6-B9DF-8F50452224B6Q54329346-553CB576-4C96-4CE4-9580-78E3C7D05B75
P2860
RASSF1A, BLU, NORE1A, PTEN and MGMT expression and promoter methylation in gliomas and glioma cell lines and evidence of deregulated expression of de novo DNMTs.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
RASSF1A, BLU, NORE1A, PTEN and ...... d expression of de novo DNMTs.
@en
RASSF1A, BLU, NORE1A, PTEN and ...... d expression of de novo DNMTs.
@nl
type
label
RASSF1A, BLU, NORE1A, PTEN and ...... d expression of de novo DNMTs.
@en
RASSF1A, BLU, NORE1A, PTEN and ...... d expression of de novo DNMTs.
@nl
prefLabel
RASSF1A, BLU, NORE1A, PTEN and ...... d expression of de novo DNMTs.
@en
RASSF1A, BLU, NORE1A, PTEN and ...... d expression of de novo DNMTs.
@nl
P2093
P2860
P1433
P1476
RASSF1A, BLU, NORE1A, PTEN and ...... ed expression of de novo DNMTs
@en
P2093
Aiala Lorente
Edurne Urdangarín
Paula Lázcoz
Ulrike Lass
Wolf Mueller
P2860
P304
P356
10.1111/J.1750-3639.2008.00185.X
P577
2008-06-25T00:00:00Z